Literature DB >> 33910834

PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma.

Min Hye Kim1,2, Gyung Hyuk Ko1,2,3, Jeong Hee Lee1,2,3, Jong Sil Lee1,2,3, Dong Chul Kim1,2,3, Jung Wook Yang1,2,3, Hyo Jung An2,3,4, Ji Min Na1, Dae Hyun Song5,3,4.   

Abstract

BACKGROUND/AIM: Programmed death ligand-1 (PD-L1) and programmed death protein 1 (PD-1) expression levels in many tumors and their correlation with prognosis have been actively studied. However, studies on PD-1 expression and its prognostic value in clear cell renal cell carcinoma (ccRCC) are limited and controversial. In this study, we describe the expression of PD-1 and its prognostic significance and association with clinical features in patients with ccRCC.
MATERIALS AND METHODS: We obtained clinicopathological data from 166 patients with ccRCC who were treated at Gyeongsang National University Hospital, Jinju, Korea between January 2000 and December 2009. Tissue microarray blocks were made using representative paraffin blocks of ccRCC specimens. Two pathologists analyzed PD-L1 and PD-1 expression in both tumor and inflammatory cells.
RESULTS: PD-1 expression in tumor-infiltrating inflammatory cells was significantly correlated with unfavorable disease-free survival (DFS) (p<0.001) and disease-specific survival (DSS) (p=0.002) in the univariate analysis. A statistically significant correlation between PD-1 expression and unfavorable DFS (p=0.025) was observed in the multivariate analysis.
CONCLUSION: PD-1 expression in tumor-infiltrating inflammatory cells serves as an independent prognostic factor for unfavorable DSS in patients with ccRCC. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Clear cell renal cell carcinoma; PD-1; immuno - histochemistry; prognosis; survival analysis

Mesh:

Substances:

Year:  2021        PMID: 33910834      PMCID: PMC8193304          DOI: 10.21873/invivo.12409

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  30 in total

Review 1.  Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Authors:  Lieping Chen
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

2.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Authors:  B Escudier; C Porta; M Schmidinger; N Rioux-Leclercq; A Bex; V Khoo; V Grünwald; S Gillessen; A Horwich
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

3.  Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study.

Authors:  Aziza Nassar; Anuradha Radhakrishnan; Isabella A Cabrero; George A Cotsonis; Cynthia Cohen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-10

4.  Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.

Authors:  Kosuke Ueda; Shigetaka Suekane; Hirofumi Kurose; Katsuaki Chikui; Makoto Nakiri; Kiyoaki Nishihara; Mitsunori Matsuo; Akihiko Kawahara; Hirohisa Yano; Tsukasa Igawa
Journal:  Urol Oncol       Date:  2018-08-18       Impact factor: 3.498

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.

Authors:  Tatsuro Tamura; Masaichi Ohira; Hiroaki Tanaka; Kazuya Muguruma; Takahiro Toyokawa; Naoshi Kubo; Katsunobu Sakurai; Ryosuke Amano; Kenjiro Kimura; Masatsune Shibutani; Kiyoshi Maeda; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

7.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Authors:  Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Igor Frank; Eugene D Kwon; Amy L Weaver; Alexander S Parker; Horst Zincke
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

Review 8.  Immune therapy for kidney cancer: a second dawn?

Authors:  David F McDermott; Michael B Atkins
Journal:  Semin Oncol       Date:  2013-08       Impact factor: 4.929

9.  PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.

Authors:  Katia R M Leite; Sabrina T Reis; José Pontes Junior; Marcelo Zerati; Daniel de Oliveira Gomes; Luiz H Camara-Lopes; Miguel Srougi
Journal:  Diagn Pathol       Date:  2015-10-15       Impact factor: 2.644

10.  Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas.

Authors:  Arezoo Rasti; Mitra Mehrazma; Zahra Madjd; Maryam Abolhasani; Leili Saeednejad Zanjani; Mojgan Asgari
Journal:  Sci Rep       Date:  2018-08-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.